Evidence map›Paper›PMID 11563046›Full record

ReviewNucleosides, nucleotides & nucleic acids

Ribose modified nucleosides and nucleotides as ligands for purine receptors.

K A Jacobson, R G Ravi, E Nandanan, H S Kim, S Moro, Y C Kim, K Lee, D Barak, V E Marquez, X D Ji

Abstract readReview
In one paragraph

Review in Nucleosides, nucleotides & nucleic acids. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Enhancement of Nucleoside Production inBioMed research international · 2017
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

K A JacobsonMolecular Recognition Section, LBC, NIDDK, National Inst. of Health, Bethesda, Maryland 20902, USA.
R G Ravi
E Nandanan
H S Kim
S Moro
Y C Kim
K Lee
D Barak
V E Marquez
X D Ji

Funding

Drugs that Act at Adenosine ReceptorsZ01DK031117 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 1991 to 2008
$854k
PROSTHETIC GROUPS FOR RADIOLABELING OF FUNCTIONALIZED DRUGS AND PEPTIDESZ01DK031116 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 1991 to 2008
$769k
Intramural NIH HHS Z01 DK031116Intramural NIH HHS Z01 DK031117
6 · The paper itself

Abstract

Molecular modeling of receptors for adenosine and nucleotide (P2) receptors with docked ligand, based on mutagenesis, was carried out. Adenosine 3',5'-bisphosphate derivatives act as selective P2Y1 antagonists/partial agonists. The ribose moiety was replaced with carbocyclics, smaller and larger rings, conformationally constrained rings, and acyclics, producing compounds that retained receptor affinity. Conformational constraints were built into the ribose rings of nucleoside and nucleotide ligands using the methanocarba approach, i.e. fused cyclopropane and cyclopentane rings in place of ribose, suggesting a preference for the Northern (N) conformation among ligands for P2Y1 and A1 and A3ARs.

Indexed as

AnimalsDrug DesignHumansLigandsNucleosidesNucleotidesPurinergic P1 Receptor AgonistsPurinergic P1 Receptor AntagonistsPurinergic P2 Receptor AgonistsPurinergic P2 Receptor AntagonistsRatsReceptors, Purinergic P1Receptors, Purinergic P2Receptors, Purinergic P2Y1RiboseLigandsNucleosidesNucleotidesP2RY1 protein, humanPurinergic P1 Receptor AgonistsPurinergic P1 Receptor AntagonistsPurinergic P2 Receptor AgonistsPurinergic P2 Receptor AntagonistsReceptors, Purinergic P1Receptors, Purinergic P2Receptors, Purinergic P2Y1Ribose

Identifiers

PMID11563046
PMCPMC4955583

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.